INmune Bio (INMB) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease
GlobeNewswireNov 13 09:00 ET
Inmune Bio Emerges as Biotech Innovator in 2023
TipRanksNov 13 06:30 ET
INmune Bio Holds an Investor and Analyst Webinar
TipRanksNov 7 11:20 ET
Maxim Group Maintains INmune Bio(INMB.US) With Buy Rating, Maintains Target Price $22
Moomoo NewsNov 7 08:31 ET · Ratings
Inmune Bio's Promising Pipeline and Financial Stability Justify Buy Rating
TipRanksNov 7 08:05 ET · Ratings
INmune Bio | 8-K: INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update
SECNov 1 16:27 ET

Comments

Trytosaveabit

Nov 13 08:06

Update

$INmune Bio (INMB.US)$ Reuters· 5 mins ago
INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease

Jaguar8

Oct 25 00:20

Put on list. Good PR re myelination study.

$INmune Bio (INMB.US)$

2

Trytosaveabit

Oct 24 14:05

News

$INmune Bio (INMB.US)$ INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination
1 MINUTE AGO, 3:03 PM EDT
VIA GLOBENEWSWIRE
INMB
SHARE
Data from Animal Model Study Demonstrate XPro™ converts microglia from a demyelinating cell to a remyelinating cell
Multi-year study published has implications for many CNS diseases including Alzheimer's

3

Jaguar8

Oct 24 14:03

NEWS

$INmune Bio (INMB.US)$
INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination
INmune Bio (NASDAQ: INMB) announces publication in Cell Reports demonstrating XPro™'s ability to promote remyelination in demyelinating disease animal models. The study, led by Dr. Leslie Probert at Hellenic Pasteur Institute, shows that XPro1595 converts microglia from damaging to reparative cells by blocking soluble TNF. This research has implications for treating various ...

4

Moomoo Breakfast US

May 24, 2022 07:22

Columns Today's pre-market stock movers: SNAP, FB, GOOG, TWTR and more

Gainers:
• $SpringWorks Therapeutics (SWTX.US)$ +19.2% (Nirogacestat Achieved Primary and All Key Secondary Endpoints in Phase3DeFi Trial )
• $Roivant Sciences (ROIV.US)$ +7.1% (FDA has approved VTAMA (tapinarof) cream)
• $Ocugen (OCGN.US)$ +5.9% (announces that it is diversifying its innovative pipeline by introducing a Phase 3 cell therapy platform technology called Ne?Cart)
• $Champion Homes (SKY.US)$ +4.4% (In reaction to earnings）
• $NetEase (NTES.US)$ +4.1% (In...

11

INMB INmune Bio

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target